Lv6
1820 积分 2022-05-22 加入
Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases
13天前
已完结
A critical review of RAF inhibitors in BRAF-mutated glioma treatment
2个月前
已关闭
An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions
2个月前
已完结
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
9个月前
已完结
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
10个月前
已完结
Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms
10个月前
已完结
BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets
10个月前
已完结
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
11个月前
已完结
UncommonEGFRmutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)
1年前
已关闭
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
1年前
已完结
皖公网安备34019202002308
